ArticleThe Korean journal of internal medicine2015
Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy.
Article in The Korean journal of internal medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Alcohol increases treatment failure for Helicobacter pylori eradication in Asian populations.BMC gastroenterology · 2023Pooled it
- Effectiveness of eradication therapy for Helicobacter pylori infection in Africa: a systematic review and meta-analysis.BMC gastroenterology · 2023Pooled it
- Early versus Late Eradication ofGut and liver · 2025Trial
- Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized study.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2018Trial
- Sex-Specific Differences in Helicobacter pylori Eradication Outcomes: Treatment Success and Adverse Events in a Single Tertiary Center in South Korea.The Korean journal of helicobacter and upper gastrointestinal research · 2026Article
- Optimizing the Routine Use of Clinical Guidelines by Addition of Supplements (Probiotics and/or Bismuth) toAntibiotics (Basel, Switzerland) · 2025Article
- Novel Drug-like HsrA Inhibitors Exhibit Potent Narrow-Spectrum Antimicrobial Activities againstInternational journal of molecular sciences · 2024Article
- Predictors of Successful First-LineAntibiotics (Basel, Switzerland) · 2024Article
- Antibiotic Resistance ofJournal of Korean medical science · 2024Review
- Article
- Development and validation of next-generation sequencing panel for personalizedFrontiers in cellular and infection microbiology · 2024Article
- Optimal treatment duration of bismuth-containing quadruple therapy in Helicobacter pylori infection: A retrospective study.Medicine · 2023Article
- Novel Mutations Conferring Amoxicillin Resistance inAntibiotics (Basel, Switzerland) · 2023Article
- Antimicrobial Resistance Molecular Mechanisms ofAntibiotics (Basel, Switzerland) · 2023Article
- Factors Affecting the Intraluminal Therapy forMicroorganisms · 2022Article
- Efficacy of Twice a Day Bismuth Quadruple Therapy for Second-Line Treatment ofJournal of personalized medicine · 2022Article
- Which is the best choice forPrzeglad gastroenterologiczny · 2022Article
- Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2021Article
- Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes forGut and liver · 2021Article
- Evaluation of the Effectiveness ofMedicina (Kaunas, Lithuania) · 2021Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsTrends in successful eradication of Helicobacter pylori using first-line triple therapy, consisting of a proton pump inhibitor, amoxicillin, and clarithromycin, have been understudied. We evaluated H. pylori eradication rates at a single center over the last 10 years and identified risk factors related to eradication failure.
methodsThis study included 1,413 patients who were diagnosed with H. pylori infection and received 7 days of triple therapy between January 2003 and December 2012. We investigated H. pylori eradication rates retrospectively with respect to the year of therapy, as well as demographic and clinical factors. H. pylori eradication was confirmed by a (13)C-urea breath test or a rapid urease test at least 4 weeks after the completion of triple therapy.
resultsThe overall H. pylori eradication rate was 84.9%. Annual eradication rates from 2003 to 2012 were 93.5%, 80.0%, 87.2%, 88.5%, 92.0%, 88.3%, 85.7%, 84.1%, 83.7%, and 78.8%, respectively, by per-protocol analysis. The eradication rate with first-line triple therapy decreased during the last 10 years (p = 0.015). Multivariate analysis showed that female gender (odds ratio [OR], 1.69; 95% confidence interval [CI], 1.12 to 2.55) and smoking (OR, 1.61; 95% CI, 1.05 to 2.47) were associated with the failure of H. pylori eradication therapy.
conclusionsThe efficacy of first-line triple therapy for H. pylori infection has decreased over the last 10 years, suggesting an increase in antibiotic-resistant H. pylori strains. Thus, other first-line therapies may be necessary for H. pylori eradication in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.